Identifying Gene Modifiers of Melanoma and Pancreatic Cancer Susceptibility

Overview

About this study

The purpose of this study is to understand the interplay of factors increasing susceptibility and expression of pancreatic cancer and melanoma to develop new diagnostic and chemopreventive regimens.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria (Cases):

Must be a known mutation carrier of CDKN2A.
Have participated in 354-06, 355-06, or 16-005414.
Able and willing to provide a skin biopsy.
Able and willing to provide a blood specimen.

Inclusion Criteria (Family Controls):

Known not to be a mutation carrier of CDKN2A.
Have participated in 354-06, 355-06, or 16-005414.
Able and willing to provide a skin biopsy.
Able and willing to provide a blood specimen.

Exclusion Criteria:

Non-English speaking.
Unable to complete informed consent.
Unable to complete skin survey supplement.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Gloria Petersen, Ph.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Gloria Petersen, Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials